OR WAIT null SECS
Patricia Van Arnum was executive editor of Pharmaceutical Technology.
July 02, 2006
Select large custom manufacturers expand capacity, private equity firms buy companies in transition, and players from India and China build their positions.
Pharmaceutical Technology provides perspective on pharmaceutical manufacturing activity, assessing the product portfolios, prescription volumes, revenues, and capital spending plans of more than 500 drug-makers. Novartis leads in diversity, with 889 products; Pfizer leads in number of scrips (352 million) and revenue ($44 billion). And generics companies are coming up on the inside.
June 29, 2006
The US Food and Drug Administration (Rockville, MD) approved the first generic versions of "Zocor" (simvastatin), the anticholesterol drug by Merck & Co., Inc. (Whitehouse Station, NJ).
Pfizer, Inc. (New York, NY) reports the United Kingdom's Court of Appeal has upheld the exclusivity of the main patent covering atorvastatin, the active ingredient in "Lipitor."
Johnson & Johnson Company (New Brunswick, NJ) agreed to buy the consumer healthcare business of Pfizer, Inc. (New York, NY) for $16.6 billion in cash.
June 22, 2006
Pfizer, Inc. (New York, NY) will phase out manufacturing operations in Groton, Connecticut, eliminating roughly 300 jobs.